Novel Oncogenic Protein Kinase Inhibitors for Cancer Therapy

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 17, 14 Issues, 2017

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Institut de Chimie de Clermont-Ferrand
Université Clermont Auvergne

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Novel Oncogenic Protein Kinase Inhibitors for Cancer Therapy

Anti-Cancer Agents in Medicinal Chemistry, 4(5): 449-455.

Author(s): Tomi K Sawyer.

Affiliation: ARIAD Pharmaceuticals, Inc., 26 Landsdowne St., Cambridge, MA 01772, USA.


Small-molecule drug discovery for cancer therapy is making extraordinary progress within the realm of advancing novel oncogenic protein kinase inhibitor lead compounds of significant impact to both basic research and clinical testing. In this perspective, structure- and mechanism-based drug design are highlighted relative to such progress. Also, evolving concepts in novel oncogenic protein kinase inhibitor drug discovery is highlighted relative to therapeutic target selectivity, including the recent identification of oncogenic kinase mutants effecting drug-resistance or enhanced drug susceptibility to small-molecule inhibitors.


oncogenic protein kinase, structure-based drug design, mechanism-based drug design, receptor tyrosine kinase, non-receptor tyrosine kinase, non-receptor serine/threonine kinase, atp binding site, protein kinase selectivity, sti-571, bms-354825.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 4
Issue Number: 5
First Page: 449
Last Page: 455
Page Count: 7
DOI: 10.2174/1568011043352830
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science